Eurand N.V. (EURX) - Financial and Strategic Analysis Review

Document Sample
Eurand N.V. (EURX) - Financial and Strategic Analysis Review Powered By Docstoc
					                 Eurand N.V. (EURX) - Financial and Strategic Analysis Review

       Reference Code: GDPH56330FSA                                                                                      Publication Date: JUL 2010

       Olympic Plaza, Fred.                   Phone                                                 Revenue
                                                               +31 20 6732744                                         121 (million EUR)
       Roeskestraat 123
       Amsterdam                              Fax                                                   Net Profit        -5.90 (million EUR)
       1076 EE                                Website          www.eurand.com                       Employees         620
       Netherlands                            Exchange         EURX [NASDAQ]                        Industry          Pharmaceuticals & Healthcare

      Company Overview
       Eurand N.V. (Eurand) is a pharmaceutical company engaged in the development, manufacturing and commercialization of
       enhanced pharmaceutical and biopharmaceutical products. It utilises its proprietary drug formulation technologies such as
       Bioavailability Enhancement, Controlling Drug Release, Dosage Form and Drug Targeting to develop a diverse product portfolio
       in a range of therapeutic areas. The company’s lead product EUR-1008 is pancreatic enzyme replacement product (PEP) used
       for the treatment of Exocrine Pancreatic Insufficiency (EPI), which is approved by FDA on June 2008. The company is
       headquartered in Amsterdam, Netherlands.

      Key Executives                                                                SWOT Analysis
                    Name                                  Title                     Eurand N.V., SWOT Analysis
      Gearoid M. Faherty                   Chairman                                 Strengths                  Weaknesses

      Rolf A. Classon                      Director
                                                                                    Successful Integration              Limited Distribution Network
      William J. Jenkins, MD               Director
      Nicholas J. Lowcock                  Director                                 Patents and Proprietary             Dependence on Small Group
                                                                                    Technology                          of Customers
      Angelo C. Malahias                   Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                    Opportunities                       Threats
      Share Data
       Eurand N.V.                                                                  Product Pipeline                    Competition from Generic
       Share Price (EUR) as on 20-Jul-2010                                8.60                                          Products

                                                                         -0.13      Target Market: Exocrine
       EPS (EUR)
                                                                                    Pancreatic Insufficiency            Dependence on Sole Supplier
       Market Cap (million EUR)                                            320

       Enterprise Value (million EUR)                                      304

       Shares Outstanding (million)                                            48   Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research       GlobalData
       G
				
DOCUMENT INFO
Description: Eurand N.V. (Eurand) is a pharmaceutical company engaged in the development, manufacturing and commercialization of enhanced pharmaceutical and biopharmaceutical products. It utilises its proprietary drug formulation technologies such as Bioavailability Enhancement, Controlling Drug Release, Dosage Form and Drug Targeting to develop a diverse product portfolio in a range of therapeutic areas. The company’s lead product EUR-1008 is pancreatic enzyme replacement product (PEP) used for the treatment of Exocrine Pancreatic Insufficiency (EPI), which is approved by FDA on June 2008. The company is headquartered in Amsterdam, Netherlands. Eurand N.V. Key Recent Developments Jun 16, 2010 Eurand Appoints Jean Louis Anspach As President Of US Pharmaceuticals Business May 14, 2010 Eurand Reports Net Income Of EUR0.4 Million For Q1 2010 Mar 04, 2010 Eurand Reports Net Loss Of EUR3.9 Million In Q4 2009 Feb 16, 2010 Eurand Wins US Patent for ZENPEP Delayed-Release Capsules Nov 30, 2009 Eurand Introduces Zenpep Capsules This comprehensive SWOT profile of Eurand N.V. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, servi
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.